Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 09, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,500,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,186.18 pence per share.
- Treasury Holdings: 485,879,158 shares (representing 8.77% of total voting rights).
- Shares in Issue: 5,539,380,379 shares (excluding Treasury shares).
Material Changes
The material change reported is the increase in the company's Treasury share holdings following the purchase of 2.5 million shares on November 09, 2007. This transaction reduces the number of shares available for trading in the open market and increases the percentage of voting rights held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 2,500,000 shares by the price of 1,186.18 pence.
- Confirm the updated total voting rights denominator (5,539,380,379 shares) for compliance with disclosure thresholds.
- Note that the company intends to hold the repurchased shares in Treasury rather than canceling them immediately.
- Recognize that this filing does not contain operational or financial performance data for the period.